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The immunosuppressive tumor microenvironment per-
turbs numerous immune regulatory networks and usurps
host antitumor immunity. We discovered that tumor
interferes with host hematopoietic Notch system in lung
cancer patients. The resultant decrease in immune Notch
signaling could be a major causative link in the adequate
induction of antitumor immunity. Interestingly, we
observed that administration of the FDA- approved pro-
teasome inhibitor drug Bortezomib (which also sensitizes
tumors to death signals) to tumor bearing mice can
restore Notch signaling in lymphoid cells without increas-
ing tumor cell proliferation or clonogenicity. Moreover,
Bortezomib administration altered Notch receptor and
ligand expression pattern and increased the expression of
Notch target genes Hes1, Hey1 and deltex1 in thymus,
lymph node and spleen. Bortezomib administration in
tumor bearing mice increased IFN-g production by T cells
while the proportion of regulatory T cells was decreased.
Our results indicate that the activation of Hes1 and Hey1
is mediated via inhibition of NFkB pathway while deltex1
activation is mediated by PI3K pathway. In another set of
experiment, we observed that administration of Bortezo-
mib along with adoptive CD8+ T cells transfer to tumor-
bearing mice resulted in the reduction of tumor nodules,
increased apoptosis and improve overall survival of mice.
Our results clearly indicate that combining Bortezomib
with adoptive T cell therapy can sustain T cell activation
and function and, thus, enhances tumor immune surveil-
lance. We are also elucidating a microRNA signature regu-
lating immune Notch signaling. Our preliminary data
suggest the role of miR-155 and miR-34a in Bortezomib
induced regulation of T cell activation. The potential of
Bortezomib to modulate anti-tumor Notch signaling and
to enhance T cell activity presents exciting opportunities.
Therapeutic restoration of immune Notch signaling by
Bortezomib could help to break tumor resistance, enhance
immune surveillance and sustain robust anti-tumor
immunity.
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